Abiraterone --- CYP17 inhibitor Abiraterone (CB-7598)

Bioss Antibodies

Abiraterone --- CYP17 inhibitor Abiraterone (CB-7598) [154229-19-3]

16

Research Use Only

98.0

Abiraterone is the first-in-class potent and selective CYP17 (cytochrome P450 17alpha-hydroxylase-17, 20-lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration-resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication, the structures of cytochrome P450 17A1 with abiraterone was released. A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway.

-20°C

51202000